Amylyx Pharmaceuticals (AMLX) Gains from Sales and Divestitures (2023 - 2026)

Amylyx Pharmaceuticals' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $676314.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures fell 3.45% year-over-year to $676314.0; the TTM figure through Mar 2026 stood at $676314.0 (down 3.45% YoY), while the FY2025 annual figure was $1.2 million, up 68.82% from the prior year.
• Gains from Sales and Divestitures was $676314.0 for Q1 2026 at Amylyx Pharmaceuticals, down from $1.2 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.2 million in Q4 2025 to a low of $146694.0 in Q1 2023.
• Historically, Gains from Sales and Divestitures has averaged $544999.8 across 4 years, with a median of $676314.0 in 2026.
• The sharpest annual moves came in 2024 and 2026: Gains from Sales and Divestitures surged 306.16% in 2024, then decreased 3.45% in 2026.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $185045.0 in 2023, then jumped by 284.89% to $712218.0 in 2024, then soared by 68.82% to $1.2 million in 2025, then slumped by 43.75% to $676314.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $676314.0 (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.